PEDIATRIC AIDS/LYMPHOMA NETWORK

儿科艾滋病/淋巴瘤网络

基本信息

批准号：
2096655
负责人：
SHARON B. MURPHY
金额：
$ 32.35万
依托单位：
LURIE CHILDREN'S HOSPITAL OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
1991
资助国家：
美国
起止时间：
1991-07-16 至 1995-06-30
项目状态：
已结题

项目摘要

The seriousness of the problem of pediatric AIDS is increasing; and, judging by the experience of adults with AIDS, there is a high likelihood that there will be increasing numbers of opportunistic lymphomas occurring in these immunodeficient children and adolescents. To address the present dearth of knowledge in this area, the aim of this project is to establish a nation-wide network of investigators with expertise in pediatric lymphomas and AIDS and thus provide a mechanism for conduct of studies of the therapy and biology of these disorders. Cases of pediatric AIDS-associated lymphomas will be contributed to the network by the member institutions of the Pediatric Oncology Group (POG), by hemophilia treatment centers (HTCs) and AIDS Clinical Trials Units (ACTUs) located in POG centers, by selected institutions of the Children's Cancer Study Group (CCSG), by the TriServices (Army, Navy, Air Force) military pediatric HIV program, and by centers connected with cohorts of the Women Infant Transmission Study (WITS). By establishment of this network of federally-funded investigators, we expect to capture the majority of pediatrics AIDS-associated lymphomas occurring in the United States over the next three years. The objectives of our studies are to integrate Phase I-III therapeutic trials of anti-cancer and anti-retroviral treatments with correlative molecular biologic and virologic studies of the human immunodeficiency virus (HID), Epstein-Barr virus (EBV), cytomegalovirus (CMV), and other herpes viruses. Our methodologic approach to the Phase II-III clinical trials will mirror the current front-line POG NHL protocols for newly-diagnosed non-HIV-infected non-Hodgkin's lymphoma patients, i.e., a control group for outcome analyses, while new agents and biologics will be tested in Phase I trials. Our hypothesis is that the host viral burden of HIV, EBV, HHV6 and CMV, assessed by quantitative culture of infectious virus and by quantitative polymerase chain reaction (PCR), will be directly related to toxicity of treatment with resultant reduction in dose intensity and increased likelihood of adverse outcome, either from disease progression or treatment-related death. We expect the resultant information to be important in future design of improved therapies which will minimize proliferation and viral-related toxicities. Complementing these clinical trials, we will establish centralized cell, sera, and tissue repositories and characterize and classify tumor tissues for origin, oncogene (c-myc) rearrangements, and viral-relatedness by PCR and in situ hybridization for viral genomes. All clinical and biologic data and analyses will be managed by a central statistical center, co-resident with the POG Statistical Office. By these coordinated efforts, we expect to foster effective treatments for pediatric AIDS-related lymphomas and facilitate collaborative interactions between laboratory scientists and clinicians.

小儿艾滋病问题的严重性正在增加。和，从成年人的艾滋病经验来看，很有可能机会性淋巴瘤数量越来越多发生在这些免疫缺陷的儿童和青少年中。解决目前在这一领域的知识缺乏，该项目的目的是建立具有专业知识的调查人员网络小儿淋巴瘤和艾滋病，从而提供了导致的机制这些疾病的疗法和生物学的研究。小儿艾滋病相关淋巴瘤病例将有助于小儿肿瘤学集团（POG）的成员机构的网络，由血友病治疗中心（HTC）和AIDS临床试验单元（ACTUS）位于POG中心，由选定的机构 Triservices（陆军，海军，空中）儿童癌症研究小组（CCSG）武力）军事小儿艾滋病毒计划，并与与之相关的中心女性传播研究（WITS）的同类。通过建立在这个由联邦资助的调查人员网络中，我们希望捕获大多数儿科艾滋病相关的淋巴瘤发生在美国未来三年。我们研究的目标是整合I-III期治疗期与相关的抗癌和抗逆转录病毒治疗的试验人类免疫缺陷的分子生物学和病毒学研究病毒（HID），爱泼斯坦 - 巴尔病毒（EBV），巨细胞病毒（CMV）和其他疱疹病毒。我们对II-III期临床的方法学方法试验将反映当前的前线POG NHL协议新诊断的非HIV未感染的非霍奇金淋巴瘤患者，即一个用于结果分析的对照组，而新的代理商和生物制剂将在I期试验中进行测试。我们的假设是宿主病毒 HIV，EBV，HHV6和CMV的负担，通过定量培养传染病和通过定量聚合酶链反应（PCR），将与治疗的毒性直接相关剂量强度的降低和不良预后的可能性增加，来自疾病进展或与治疗相关的死亡。我们期望最终的信息在未来的改进设计中很重要可以最大程度地减少增殖和病毒相关毒性的疗法。与这些临床试验相辅相成，我们将建立集中式细胞，血清和组织存储库并表征和分类肿瘤组织对于起源，癌基因（C-MYC）重排和PCR病毒相关性并原位杂交病毒基因组。所有临床和生物学数据和分析将由中央统计中心管理，与POG统计办公室共同居住。通过这些协调努力，我们希望为小儿促进有效的治疗与AIDS相关的淋巴瘤并促进实验室科学家和临床医生。